

Francesca Assogna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9247842/publications.pdf>

Version: 2024-02-01

64
papers

3,295
citations

172457

29
h-index

168389

53
g-index

68
all docs

68
docs citations

68
times ranked

6400
citing authors

#	ARTICLE	IF	CITATIONS
1	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , 2018, 84, 644-654.	1.3	627
2	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	7.6	374
3	Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. <i>Molecular Psychiatry</i> , 2014, 19, 1143-1149.	7.9	293
4	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
5	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. <i>NeuroImage</i> , 2020, 218, 116956.	4.2	135
6	Hippocampal abnormalities and memory deficits in Parkinson disease. <i>Neurology</i> , 2012, 78, 1939-1945.	1.1	123
7	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. <i>American Journal of Psychiatry</i> , 2020, 177, 834-843.	7.2	120
8	The recognition of facial emotion expressions in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, 835-848.	0.7	97
9	Mapping Cortical and Subcortical Asymmetry in Obsessive-Compulsive Disorder: Findings From the ENIGMA Consortium. <i>Biological Psychiatry</i> , 2020, 87, 1022-1034.	1.3	73
10	Chronic Pain in the Elderly with Cognitive Decline: A Narrative Review. <i>Pain and Therapy</i> , 2019, 8, 53-65.	3.2	71
11	Amygdala and hippocampus volumetry and diffusivity in relation to dreaming. <i>Human Brain Mapping</i> , 2011, 32, 1458-1470.	3.6	67
12	Anhedonia in Parkinson's disease: A systematic review of the literature. <i>Movement Disorders</i> , 2011, 26, 1825-1834.	3.9	60
13	The ENIGMA Stroke Recovery Working Group: Big data neuroimaging to study brain-behavior relationships after stroke. <i>Human Brain Mapping</i> , 2022, 43, 129-148.	3.6	54
14	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2583-2594.	3.9	54
15	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 867-876.	1.8	49
16	Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters. <i>Translational Psychiatry</i> , 2020, 10, 342.	4.8	43
17	Alexithymia in Parkinson's disease: A systematic review of the literature. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 1-11.	2.2	41
18	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 133-141.	1.2	38

#	ARTICLE	IF	CITATIONS
19	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson's Disease and Is Associated with Motor Symptom Severity. PLoS ONE, 2013, 8, e65352.	2.5	38
20	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. Sensors, 2021, 21, 128.	3.8	38
21	Does a volume reduction of the parietal lobe contribute to freezing of gait in Parkinson's disease?. Parkinsonism and Related Disorders, 2014, 20, 1101-1103.	2.2	36
22	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. Parkinsonism and Related Disorders, 2015, 21, 1096-1100.	2.2	36
23	Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients. Human Brain Mapping, 2016, 37, 1136-1147.	3.6	36
24	Elevated plasma ceramide levels in post-menopausal women: a cross-sectional study. Aging, 2019, 11, 73-88.	3.1	36
25	Polygenic determinants of white matter volume derived from GWAS lack reproducibility in a replicate sample. Translational Psychiatry, 2014, 4, e362-e362.	4.8	35
26	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease. European Neuropsychopharmacology, 2015, 25, 69-76.	0.7	35
27	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. JMIR MHealth and UHealth, 2020, 8, e16414.	3.7	33
28	Met158 variant of the catechol-O-methyltransferase genotype is associated with thicker cortex in adult brain. Neuroscience, 2010, 167, 809-814.	2.3	32
29	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. Parkinsonism and Related Disorders, 2018, 54, 62-67.	2.2	32
30	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 50-56.	2.2	31
31	Drug Choices and Advancements for Managing Depression in Parkinson's Disease. Current Neuropharmacology, 2020, 18, 277-287.	2.9	31
32	Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. Frontiers in Aging Neuroscience, 2013, 5, 37.	3.4	30
33	Morphological correlates of MAO A VNTR polymorphism: New evidence from cortical thickness measurement. Behavioural Brain Research, 2010, 211, 118-124.	2.2	27
34	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. Neurological Sciences, 2019, 40, 1377-1382.	1.9	27
35	Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study. European Journal of Neurology, 2012, 19, 172-175.	3.3	26
36	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 871-875.	2.2	23

#	ARTICLE	IF	CITATIONS
37	Safinamide improves executive functions in fluctuating Parkinsonâ€™s disease patients: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 273-277.	2.8	19
38	MAO A VNTR polymorphism and amygdala volume in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 87-91.	1.8	18
39	The neuropsychological correlates of cognitive insight in healthy participants. <i>Applied Cognitive Psychology</i> , 2011, 25, 927-932.	1.6	18
40	The early course of affective and cognitive symptoms in de novo patients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2014, 261, 1126-1132.	3.6	14
41	Anti-inflammatory Effects of Homotaurine in Patients With Amnesic Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 285.	3.4	14
42	Dysbindin Câ€™Aâ€™T haplotype is associated with thicker medial orbitofrontal cortex in healthy population. <i>NeuroImage</i> , 2011, 55, 508-513.	4.2	12
43	Increased expression of Interleukin-18 receptor in blood cells of subjects with Mild Cognitive Impairment and Alzheimerâ€™s disease. <i>Cytokine</i> , 2013, 61, 360-363.	3.2	12
44	Effectiveness of a Family Support Intervention on Caregiving Burden in Family of Elderly Patients With Cognitive Decline After the COVID-19 Lockdown. <i>Frontiers in Psychiatry</i> , 2021, 12, 590104.	2.6	12
45	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. <i>Depression and Anxiety</i> , 2013, 30, 85-91.	4.1	11
46	Action Observation With Dual Task for Improving Cognitive Abilities in Parkinsonâ€™s Disease: A Pilot Study. <i>Frontiers in Systems Neuroscience</i> , 2019, 13, 7.	2.5	11
47	Orthostatic hypotension acutely impairs executive functions in Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2018, 39, 1459-1462.	1.9	10
48	Rasagiline for dysexecutive symptoms during wearing-off in Parkinsonâ€™s disease: a pilot study. <i>Neurological Sciences</i> , 2018, 39, 141-143.	1.9	10
49	Rotigotine for anxiety during wearing-off in Parkinsonâ€™s disease with dementia. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 601-603.	2.9	9
50	Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinsonâ€™s disease patients. <i>Metabolomics</i> , 2019, 15, 74.	3.0	9
51	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. <i>Brain and Behavior</i> , 2019, 9, e01448.	2.2	9
52	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonâ€™s Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 51.	2.5	9
53	Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 389.	2.2	8
54	Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 92.	3.4	8

#	ARTICLE	IF	CITATIONS
55	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. <i>Frontiers in Genetics</i> , 2021, 12, 651971.	2.3	8
56	Subclinical Cognitive and Neuropsychiatric Correlates and Hippocampal Volume Features of Brain White Matter Hyperintensity in Healthy People. <i>Journal of Personalized Medicine</i> , 2020, 10, 172.	2.5	7
57	Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators. <i>Journal of Personalized Medicine</i> , 2021, 11, 16.	2.5	6
58	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5
59	Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients. <i>Brain and Behavior</i> , 2018, 8, e01094.	2.2	4
60	Alexithymia in Parkinson's disease: secondary phenomenon or primary neuropsychiatric feature?. <i>Neurodegenerative Disease Management</i> , 2012, 2, 343-346.	2.2	3
61	Unraveling predictors affecting compliance to MRI in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 964-967.	2.2	2
62	Neurobiological Basis of Childhood Trauma and the Risk for Neurological Deficits Later in Life. , 2020, , 385-410.		2
63	On the relationship between side of onset and cognition in Parkinson disease: Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1481-1482.	2.2	1
64	Anhedonia in Parkinson's Disease and Other Movement Disorders. , 2014, , 265-290.		0